Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + pyrotinib + dalpiciclib + endocrine therapy
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
trastuzumab + pyrotinib + dalpiciclib + endocrine therapy is a combination therapeutic regimen being investigated for the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) breast cancer. This regimen combines multiple targeted approaches: pyrotinib, an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor targeting EGFR, HER2, and HER4; trastuzumab, a monoclonal antibody targeting the extracellular domain of HER2; dalpiciclib (SHR6390), a selective CDK4/6 inhibitor that blocks cell cycle progression; and endocrine therapy to inhibit estrogen-driven tumor growth. The combination is currently being evaluated in a Phase II clinical trial led by Peking University Cancer Hospital & Institute to improve survival outcomes in patients with HER2-positive advanced breast cancer. Pyrotinib and dalpiciclib are both developed by Jiangsu Hengrui Pharmaceutical, while trastuzumab is a standard-of-care HER2-targeted biologic.
- Brand names
- AiRuiNiAiRuiKangHerceptin
- Other names
- Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapypyrotinib-Peking University Cancer Hospital & Institute-breast cancer
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)EGFR (Epidermal growth factor receptor)ESR1 (ERα)
Beyond the preview
Go deeper on trastuzumab + pyrotinib + dalpiciclib + endocrine therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + pyrotinib + dalpiciclib + endocrine therapy.